| 0.7658 -0.026 (-3.31%) | 02-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1 | 1-year : | 1.17 |
| Resists | First : | 0.85 | Second : | 1 |
| Pivot price | 0.78 |
|||
| Supports | First : | 0.62  |
Second : | 0.47 |
| MAs | MA(5) : | 0.77 |
MA(20) : | 0.76 |
| MA(100) : | 0.94 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60 |
D(3) : | 59.1 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 1.91 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LEXX ] has closed above bottom band by 36.6%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.8 | 0.8 - 0.8 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.76 - 0.77 | 0.77 - 0.77 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Thu, 22 Jan 2026
LEXX Strengthens Patent Portfolio with New International Approva - GuruFocus
Mon, 12 Jan 2026
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with Dehyd - GuruFocus
Tue, 30 Dec 2025
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Mon, 15 Dec 2025
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
Mon, 15 Dec 2025
Lexaria Bioscience stock plunges after $3.5M at-the-market offering - Investing.com
Mon, 15 Dec 2025
Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.354e+007 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 618 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.044e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | -83 % |
| Qtrly Rev. Growth | 522000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -250.38 |
| EBITDA (p.s.) | 841936 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.15 |
| Dividend | 0 |
| Forward Dividend | 1.06e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|